Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

Rhea-AI Summary

Lantheus Holdings (NASDAQ: LNTH) announced a poster presentation of data from its Phase 3 CONDOR study at the ASCO Virtual Meeting from June 4-8, 2021. The session will focus on PSMA-targeted imaging in patients with biochemically recurrent prostate cancer, highlighting the correct localization rate and positive predictive value.

Presenter Frederic Pouliot, M.D., Ph.D., from CHU de Québec-Université Laval will showcase abstract No. 5023. Lantheus is a leader in imaging diagnostics and therapeutics, providing a broad portfolio aimed at serious medical conditions.

Positive

• Presentation of Phase 3 CONDOR study data could enhance Lantheus' credibility in oncology.
• Opportunity to attract investor interest during a prominent medical conference.

Negative

• None.

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.

The presentation will be made available for the duration of conference.

Details for the ASCO presentation are as follows:

Session Title: Poster Session: Genitourinary Cancer – Prostate, Testicular and Penile
Title: PSMA-targeted imaging with ¹⁸F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval
Abstract No: 5023

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow^® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, please visit www.lantheus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210521005043/en/

FAQ

What is the Phase 3 CONDOR study presented by Lantheus Holdings?

The Phase 3 CONDOR study focuses on PSMA-targeted imaging for biochemically recurrent prostate cancer patients.

When is the ASCO Virtual Meeting where Lantheus will present its study?

The ASCO Virtual Meeting will take place from June 4-8, 2021.

Who is presenting the Lantheus Phase 3 CONDOR study at ASCO?

Frederic Pouliot, M.D., Ph.D., from CHU de Québec-Université Laval will present the study.

What is the focus of Lantheus' presentation at the ASCO meeting?

The presentation will highlight the correct localization rate and positive predictive value in prostate cancer imaging.